Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Profile Name | NTRK1 G667C |
Gene Variant Detail | |
Relevant Treatment Approaches |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
NTRK1 G667C NTRK1 act mut | Advanced Solid Tumor | sensitive | Selitrectinib | Preclinical | Actionable | In a preclinical study, a cell line oncogenic mouse model expressing an NTRK1 activating mutation and a secondary resistance mutation, NTRK1 G667C, was sensitive to treatment with Selitrectinib (LOXO-195), demonstrating inhibition of tumor growth (PMID: 28578312). | 28578312 |
NTRK1 G667C NTRK1 act mut | Advanced Solid Tumor | decreased response | Larotrectinib | Preclinical | Actionable | In a preclinical study, a cell line oncogenic mouse model expressing an NTRK1 activating mutation and a secondary resistance mutation, NTRK1 G667C, demonstrated a decrease response when treated with Vitrakvi (larotrectinib) (PMID: 28578312). | 28578312 |